Approximately 15% of individuals with hemophilia A develop antibodies (inhibitors) to therapeutically infused factor VIII that interfere with F.VIII coagulant activity. By using isoelectric focusing and immunospecific detection of anti-factor VIII antibodies, inhibitor plasmas showed varied patterns of reactivity characteristic of a polyclonal response. Inhibitor plasma from patient Bt was observed to have an isolated banding pattern, or spectrotype, at pI 8.4 (SP8.4) distinct from his remaining anti-factor VmI antibodies. SP8.4 antibodies from this patient were partially purified and used to prepare monoclonal anti-idiotype antibodies. Monoclonal antibody Mab2O-2H was found to detect a spectrotype in isoelectric-focused Bt plasma identical to SP8.4 and to bind anti-factor VIII antibodies. Furthermore, Mab2O-2H binding could inhibit the binding of these anti-factor VIII antibodies to antigen, indicating that Mab2O-2H recognizes an idiotope associated with antigen binding. Mab2O-2H was also found to recognize antibodies from another inhibitor patient. This and other anti-idiotype reagents will be useful for defining genetic factors involved in the human immune response to factor VIII and in designing approaches to prevent or ameliorate this response.
Hemophilia A is a bleeding disorder, caused by a deficiency or abnormality of the plasma protein factor VIII (F.VIII). This disorder is often treated with transfused F.VIII, purified from pooled normal plasma or produced by recombinant DNA technology (1) . Unfortunately, =15% of treated patients develop anti-F.VIII antibodies that inhibit F.VIII activity (inhibitors) (2) . Since these antibodies interfere with therapy, inhibitor patients create a serious clinical challenge.
The underlying factors that predispose some patients to develop such inhibitors remain unknown. Data on F.VIII gene defects show that a number of inhibitor patients have F.VIII gene deletions, but this is not a dependable predicter of inhibitor development (for reviews, see refs. 3 and 4). A possible association between the immune response genes in the HLA complex and inhibitor formation has also been suggested, but no relationship of predictive value on an individual patient basis has been found (5, 6) . Other studies imply that naturally occurring anti-idiotypic antibodies play a role in the regulation of the F.VIII immune response and suggest a clinical applicability of anti-idiotypic reagents for F.VIII inhibitor treatment (7) (8) (9) .
Anti-idiotype antibodies have also been used as probes to study the specific variable region genes used in an immune response (10, 11) . For this reason, investigations of the idiotypic properties of human anti-F.VIII antibodies have the potential of detecting immunoglobulin variable regions associated with inhibitor susceptibility. Polyclonal rabbit antiidiotype antibodies have been produced that bind to human and murine monoclonal anti-F.VIII antibodies (8, 12) . However, such anti-idiotype antibodies have limited use since they detect a number of idiotopes present on the anti-F.VIII antibodies. Precise characterization of single idiotopes on anti-F.VIII antibodies can be studied using monoclonal antiidiotype antibodies, but such reagents have proven to be difficult to generate. This report describes the preparation of a monoclonal anti-idiotype antibody that reacts with anti-F.VIII antibodies found in two hemophilic patients. Such monoclonal anti-idiotypes against shared idiotypes will be useful for studying the diversity of idiotypic determinants in the human immune response to F.VIII and analyzing the potential role of anti-idiotypes in ameliorating the hemophilic patient's response to F.VIII. (14) . The HPLC Purification of Mab2O-2H. An SAS immunoglobulin fraction was prepared from Mab2O-2H ascites. The Mab2O-2H SAS fraction was applied to a HPLC DEAE-500 silicon-based column (Perkin-Elmer/Cetus) equilibrated in 0.1 M Hepes (pH 7.5). The sample was eluted with a salt gradient so that the final buffer was 0.1 M Hepes/1.0 M NaCl, pH 7.5. Affinity Purification of Human Anti-F.VIII Antibodies Using Mab2O-2H. HPLC RIA to Analyze the Binding of F.VIII to Mab2O-2H-AffinityPurifiled Bt Antibodies. EIA/RIA strips (Costar) were coated with goat or rabbit anti-human IgG (up to 600 ng/75 ul) for 2 hr at 24TC. The wells were washed once using TBS with 0.02% Tween 20 and blocked with 2% (wt/vol) gelatin.
MATERIALS AND METHODS
Affinity-purified antibodies diluted in 1% gelatin were added at various concentrations and incubated overnight at 240C.
The wells were washed three times and incubated with 125I-labeled F.VIII (0.95 unit/75 /4) diluted in 1% gelatin overnight. The wells were washed six times and assayed for bound 1251. Percent binding was calculated after the subtraction of background counts (wells that did not contain affinitypurified antibodies).
Competitive Binding Assay to Study the Anti-Idiotype Characteristics of Mab2O-2H. The assay was carried out as above except the affinity-purified antibody was added at 75 ng/75 /4. HPLC-purified Mab2O-2H was added with the 1251I-labeled IEF Analysis of Mab2O-2H Binding to Human Plasma. Plasma or SAS immunoglobulin fractions were focused on an IEF gel with pH 3-10 or pH 8-10.5 gradients (Pharmacia) and diffusion-blotted. The blots were blocked and incubated with Mab2O-2H solution overnight. The blots were subsequently washed, incubated with peroxidase-or alkaline phosphataselabeled goat anti-mouse IgG for 2 hr, washed, and developed.
ELISA Analysis of Mab2O-2H Binding to Human Plasma. Microtiter plates were coated with goat anti-mouse IgG + IgM (=225 ng/ml), washed, and blocked with 20% (vol/vol) normal goat serum. The wells were then incubated with or without Mab2O-2H overnight at 24°C, washed, and incubated with 1:100 dilution of human plasma (2 hr). After washing and a 2-hr incubation with peroxidase-labeled goat anti-human IgG (7.5 ng/75 ,lI), the plates were developed with a peroxidase substrate (Kirkegaard and Perry Laboratories). Binding was calculated after the subtraction of background (wells that did not contain Mab20-2H).
Measurement of F.VIII Inhibitors. Inhibition of F.VIII coagulant (F.VIII:C) activity in Bt plasma and the affinitypurified antibodies was determined using a Bethesda assay with results expressed as Bethesda units/ml (16) .
The inhibitor titer of Bt plasma before and after the removal of Mab20-2H-afflinity-purified antibodies was determined using a modified Bethesda assay. Equal volumes of pooled human plasma and a dilution of inhibitor plasma were incubated for 1 hr, instead of the customary 2-hr incubation.
Analysis of the Mab2O-2H Effect on F.VIII Inhibitors. Purified Mab2O-2H (from 1.43 ,ug/ml to 1.43 mg/ml) and Mab20-2H-affinity-purified Bt antibodies (1 Bethesda unit/ ml) were incubated for 1 hr at 37°C. The solutions were stored at -70'C until a standard Bethesda assay was performed.
F.VIII Immunoblot Analysis. Purified F.VIII (6.5 units) was partially degraded by thrombin (0.27 units) at 250C for 2 hr. The F.VIII was subjected to unreduced SDS/PAGE on Medical Sciences: Lubahn and 
.5% gels and electrophoretically transferred onto nitrocellulose. The blotted F.VIII was stained for total protein with Aurodye (Janssen Pharmaceutica) by following the manufacturer's directions. The remaining F.VIII blots were blocked for 1 hr with BLOTTO [5% (wt/vol) Carnation nonfat powdered milk/10% normal goat serum/0.1% Tween 20 in 0.014 M sodium phosphate/0.003 M KCl/0.14 M NaCI, pH 7 (PBS)]. The blotted F.VIII was incubated with Mab20-2H-affinity-purified antibodies or a 1:150 dilution of plasma in BLOTTO overnight at 240C. After three 10-min washes with 0.1% Nonidet P-40 in PBS, the blots were incubated with rabbit anti-human IgG (320 ng/ml) (Jackson ImmunoResearch) in BLOTTO for 2 hr, washed, and incubated with 125I-labeled goat anti-rabbit IgG (0.25 uCi/ml; ICN) for 2 hr.
After washing, the blots were autoradiographed.
RESULTS
IEF analysis revealed that inhibitor plasmas have anti-F.VIII antibodies over a wide pI range in a pattern typical of a polyclonal response (Fig. 1) . One patient (Bt; lane 9) also had a set of distinct closely spaced bands at pI 8.4, characteristic of the spectrotype pattern seen for a monoclonally derived immunoglobulin and separate from other anti-F.VIII antibodies in this plasma. Because of this distinct spectrotype, called SP8.4, and a high Bethesda unit titer, patient Bt plasma was used as a source of anti-F.VIII antibodies for antiidiotype production. SP8.4 antibodies were partially purified by HPLC chromatography and chromatofocusing. Since a limited amount of protein (-75 ,ug) was recovered, no attempt was made to immunospecifically purify the anti-F.VIII antibodies from other proteins of pI 8.4. The enriched anti-F.VIII antibody preparation was used for immunization in hybridoma production.
To test for the production of anti-idiotypic antibodies, the hybridoma supernatants were examined for binding to isoelectrofocused Bt proteins. Twenty-eight positive clones that demonstrated binding to Bt proteins were identified in this initial IEF screening. The majority of these clones showed binding to both Bt and normal plasma and were assumed to bind to isotypic or allotypic determinants not related to antibody specificity. Four clones, however, showed unique restricted banding patterns when binding to Bt plasma and did not bind to normal plasma, meeting the criteria used to select presumptive anti-idiotype reagents. Since Mab20-2H detected a distinct set ofbands at pI 8.4 (Fig. 2, lane 1) , it was chosen for further study. Fig. 2, lane 1) . However, the anti-F.VIII antibodies used for immunization were only partially purified, and Mab2O-2H could be reacting with any protein of pI 8.4 present in Bt plasma. To determine if Mab2O-2H was indeed reacting specifically with a subpopulation of Bt anti-F.VIII antibodies, Mab2O-2H was used as a solid-phase immunoaffinity reagent to purify antibodies from Bt plasma. The solid-phase reagent could deplete Bt plasma of antibodies recognized by Mab2O-2H (Fig. 2, lane  2) . IgG having the characteristic SP8.4 spectrotype could be eluted from the immunoaffinity reagent (Fig. 2, lane 3) . The immunoaffinity-purified Bt antibodies bound radiolabeled F.VIII in an RIA, confirming that Mab2O-2H binds to SP8.4 anti-F.VIII antibodies in Bt plasma (Fig. 3A) . The addition of Mab2O-2H inhibited the binding of radiolabeled F.VIII to the SP8. 4 antibodies by >80%o in a competitive binding assay. Control buffer and purified myeloma IgG showed no significant inhibitory activity (Fig. 3B) Fig. 4 various concentrations of Mab2O-2H did not remove this inhibiting activity. This inhibiting activity is likely to result from the above mentioned traces of additional antibody populations in the affinity-purified antibody preparation. Hence, the binding of Mab20-2H-affinity-purified Bt antibodies to F.VIII does not appear to inhibit F.VIII:C activity.
To see if Mab20-2H also binds to antibodies in other plasmas, idiotope-specific ELISAs and IEF assays were developed (Table 1) . Noninhibitor or normal plasmas tested showed no significant binding. Of the 52 inhibitor plasmas analyzed, bound to antibodies present in two inhibitor plasmas, including Bt plasma. In inhibitor plasma from patient Lc, the spectrotype detected by Mab2O-2H is at (17) . On this SDS gel, the molecular masses of the fragments were 91, 77, 69, 51, and 42 kDa. Lanes [2] [3] [4] [5] show immunoblots of the binding of anti-F.VIII antibodies to specific thrombin-cleaved F.VIII fragments. Lanes: 2, Bt plasma [2.5-hr exposure; Bt plasma also binds the 80-kDa fragment when an increased amount of this fragment is present (unpublished data)]; 3, Mab2O-2H-affinity-purified Bt antibodies (4-hr exposure); 4, Lc plasma (4.5-hr exposure); 5, Mab2O-2H-affinity-purified Lc antibodies (96-hr exposure). tMultiple bleeding dates for Bt (14-year span) and Lc (5-year span) were positive by ELISA, IEF, or both. pl 8.6 (Fig. 2, lane 5) , slightly higher than the SP8.4 antibodies detected in Bt plasma. Lc antibodies purified using Mab2O-2H-immunoaffinity resin were found to bind the 43-kDa fragment of F.VIII and its 90-kDa precursor (Fig. 4, lane 5) .
(As was the case with affinity-purified Bt antibodies, some binding to other F.VIII fragments could be detected with extended autoradiography and was assumed to be due to contaminating antibodies.) This clonal population of anti-F.VIII antibodies was found to be a subset of the anti-F.VIII antibodies in Lc plasma that bind to the 90-, 80-, 73-, and 43-kDa F.VIII thrombin-cleaved fragments (Fig. 4, lane 4) .
DISCUSSION
IEF has proven to be a powerful method for studying the clonal origin of antibodies. A monoclonal antibody derived from a single B-cell clone has a unique IEF pattern, called a spectrotype, which often consists of three to six evenly spaced bands. This pI microheterogeneity of the antibodies is due to post-translational modifications, such as various degrees of glycosylation and deamidation (19, 20) . The human immune response to some antigens, including thyroglobulin in the autoimmune disease Hashimoto-type thyroiditis and Haemophilus influenzae b capsular polysaccharide, has been shown to be oligoclonal in nature and to have distinct IEF spectrotypes (21, 22) . One would expect that each individual banding pattern is derived from a single antibody-producing clone in such a response. Although the human immune response to F.VIII is complex, some patients have unique spectrotypes that appear to be derived from a single antibody-producing clone (Fig. 1) . The SP8.4 antibodies in Bt plasma (Fig. 1, lane 9 Fig. 4 , small amounts of anti-F.VIII antibodies to other fragments could be detected, including the 50-kDa chain where Bt antibodies capable of neutralizing F.VIII activity are known to bind (23) . (ii) By making the assumptions that all inhibitors in Bt plasma are IgG and that most of the IgG in Bt plasma does not have anti-F.VIII:C activity, immunospecific purification of a clonal population of inhibiting antibodies would be expected to yield a higher specific inhibitory activity than found in plasma (13, 24) . The specific activity of the Mab20-2H-affinity-purified antibodies (0.053 Bethesda units/,ug) was 3.2 times lower than Bt plasma (0.17 Bethesda units/pg). Finally, Mab20-2H, although capable of inhibiting the binding of purified SP8.4 antibodies to 125I_ labeled F.VIII, did not inhibit the F.VIII:C neutralizing activity of the preparation. For these reasons it is likely that trace contaminating antibodies account for the Bethesda titer seen in the immunoaffinity-purified preparation of SP8.4 antibodies. Similarly, no F.VIII:C inhibitory' activity was detected in the antibodies affinity purified from Lc plasma. Hence, antibodies in Bt and Lc plasma that are recognized by Mab2O-2H appear to bind to a nonneutralizing epitope on the 43-kDa thrombin fragment of F.VIII.
Reactivity with the 43-kDa heavy chain-derived fragment is common in hemophilic inhibitor plasmas with at least 50% tested having such activity (ref. 25 and unpublished data). Some of the 43-kDa epitopes are known to be neutralizing, but this is a clear demonstration of a nonneutralizing epitope on this chain (26) . Nonneutralizing epitopes have also been reported on the B domain and 80-kDa chain of F.VIII (27, 28) . The clinical significance of such nonneutralizing antibodies is unknown although such antibodies have been demonstrated to be present in patients after the induction of tolerance to F.VIII. It has been speculated that these antibodies may somehow play a role in maintaining such tolerance (28) . Two inhibitor patients included in Table 1 , where tolerance was induced or occurred spontaneously, showed no immunoreactivity with Mab2O-2H before or after tolerance (18) .
We have demonstrated the feasibility of producing a monoclonal anti-idiotype reagent to shared epitopes present on anti-F.VIII antibodies in hemophilic inhibitor plasmas. Mab2O-2H detected antibodies in two of the 52 (3.8%) hemophilic inhibitor plasmas tested. We have also generated three other putative anti-idiotype reagents that detect other antibody populations in Bt plasma. Preliminary work shows that one of these monoclonal antibodies reacts with three inhibitor plasmas and did not react with other inhibitor or normal plasmas. This evidence suggests that this monoclonal antibody also detects a shared idiotope. Hoyer et al. (24) have briefly noted the production of monoclonal anti-idiotype reagents that appear to detect public idiotypes. Such public anti-idiotype antibodies would be useful for identifying genetic factors important in the immune response to F.VIII and for potential clinical use.
In clinical trials, anti-idiotype reagents have been useful in the treatment ofhuman B-cell lymphomas (29) . Further (31, 32) . A knowledge of the idiotypic properties of anti-F.VIII antibodies may be helpful in the optimization ofthe above procedures and development of therapies for the hemophilic inhibitor patient.
